Related Experiment Video
Updated: Jul 12, 2025

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
[Calprotectin levels in meconium measured with an automated immunoassay (Liaison® XL)]
Charlotte Oris1, Maguelonne Pons2, Emmanuelle Rochette3
1Service de Biochimie et Génétique Moléculaire, Centre de Biologie, CHU Gabriel Montpied, 58 Rue Montalembert, 63000 Clermont-Ferrand, France, Université Clermont Auvergne, Faculty of medicine, CNRS 6293, INSERM 1103, GReD, Clermont-Ferrand, France.
Insights
Newborn meconium calprotectin reference ranges were established for the first time, revealing higher physiological levels than in older children. Sex-specific differences were noted, suggesting sequential testing for accuracy.
Area of Science:
- Clinical Chemistry
- Neonatal Medicine
- Gastroenterology
Abstract:
A threshold of 50 μg fecal calprotectin per g stool sample (μg/g) is commonly used to diagnose chronic inflammatory bowel disease in adult patients and children over 4 years of age. In younger children, fecal calprotectin values are physiologically increased. For the first time, the objective of our study was to establish reference ranges in newborns for the measurement of meconium calprotectin with an automated assay (Liaison® XL, DiaSorin). A prospective study was conducted in 2022 in the Maternity Unit of the Clermont-Ferrand University Hospital, with the inclusion of full-term newborns without intestinal involvement. The quantitative automated Liaison® XL calprotectin assay was assessed on a panel of meconium samples. In our cohort of 132 term neonates, calprotectin values ranged from 21 to 855 μg/g of meconium (2,5th to 97.5th percentile) and the median value was 194 μg/g. In our cohort, only sex-related differences were observed for calprotectin values. No significant differences were found for the other factors studied (maternal or neonatal). Because of inter-individual variability, a sequential measurement of newborn calprotectin from meconium should be considered.

